NSG mice were obtained from Charles River Laboratories [Sulzfeld, Germany]. Mice were kept under specific pathogen-free conditions in individually ventilated cages in a facility controlled according to the Federation of Laboratory Animal Science Association [FELASA] guidelines. Following engraftment on Day 1, mice were presensitised by rectal application of 150 µL of 10% ethanol on Day 8 using a 1-mm cat catheter [Henry Schein, Hamburg, Deutschland]. The catheter was lubricated with Xylocain©Gel 2% [AstraZeneca, Wedel]. Rectal application was performed under general anaesthesia using 4% isoflurane. Post-application mice were kept at an angle of 30° to avoid ethanol dripping. On Day 15, the mice were challenged by rectal application of 50% ethanol following the protocol used on Day 8. For the drug treatments, DES1 [D. E. Shaw Research, New York, USA] and tofacitinib [Merck KGaA, Darmstadt, Germany] were administered daily over one period of 3 days and a second period of 4 days [Days 7–9 and 14–17, respectively], such that each period encompassed one of the two ethanol challenges [on Days 8 and 15]. The dosages were 5 mg/kg/day for DES1 and 5 mg/kg/day for tofacitinib. The dosage of infliximab [Janssen Biotech, Horsham, Pennsylvania, USA] was 6 mg/kg/day, and treatment was limited to Days 7 and 14 only. All therapeutics were dissolved in PBS and administered intraperitoneally.
Xylocain gel 2
Manufactured by AstraZeneca
Sourced in Germany
Xylocain©Gel 2% is a local anesthetic gel formulation containing lidocaine hydrochloride as the active ingredient. The gel is designed for topical application to provide localized pain relief.
Automatically generated - may contain errors
Lab products found in correlation
1 mm cat catheter, by Henry Schein (4 mentions)
Nsg mice, by Charles River Laboratories (3 mentions)
Infliximab, by Johnson & Johnson (1 mentions)
Firma cat m0512, by Merck Group (1 mentions)
Nod cg prkdcscid il2rgtm1wjl szj mice, by Charles River Laboratories (1 mentions)
Sterile saline, by B. Braun (1 mentions)
Isotype control, by BioLegend (1 mentions)
Nod scid il2rγ null mice, by Charles River Laboratories (1 mentions)
5 protocols using xylocain gel 2
1
Ethanol-Induced Colitis Model in NSG Mice
2
Colitis Induction and Therapeutic Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NSG mice were obtained from Charles River Laboratories (Sulzfeld, Germany). The mice were kept under specific pathogen-free conditions in individually ventilated cages in a facility controlled according to the Federation of Laboratory Animal Science Association (FELASA) guidelines. The age of the mice was between 6 and 8 weeks.
Following engraftment on day 1, the mice were presensitized by rectal application of 150 µL of 10% ethanol on day 8 using a 1 mm cat catheter as previously described [23 (link)] (Henry Schein, Hamburg, Deutschland). The catheter was lubricated with Xylocain©Gel 2% (AstraZeneca, Wedel, Germany). Rectal application was performed under general anesthesia using 4% isofluran. Post application, the mice were kept at an angle of 30° to avoid ethanol dripping. On day 15, the mice were challenged by rectal application of 150 µL of 50% ethanol following the protocol of day 8. On day 18, the mice were sacrificed. Therapeutic antibodies (150 µL in PBS) were applied i.p. on days 7 and 14, and small-molecule inhibitors (150 µL in PBS or 0.5% methylcellulose gel in PBS (Merck KGaA, Darmstadt, Germany, Firma Cat# M0512) were applied i.p. on days 7–9 and 14–17.
Following engraftment on day 1, the mice were presensitized by rectal application of 150 µL of 10% ethanol on day 8 using a 1 mm cat catheter as previously described [23 (link)] (Henry Schein, Hamburg, Deutschland). The catheter was lubricated with Xylocain©Gel 2% (AstraZeneca, Wedel, Germany). Rectal application was performed under general anesthesia using 4% isofluran. Post application, the mice were kept at an angle of 30° to avoid ethanol dripping. On day 15, the mice were challenged by rectal application of 150 µL of 50% ethanol following the protocol of day 8. On day 18, the mice were sacrificed. Therapeutic antibodies (150 µL in PBS) were applied i.p. on days 7 and 14, and small-molecule inhibitors (150 µL in PBS or 0.5% methylcellulose gel in PBS (Merck KGaA, Darmstadt, Germany, Firma Cat# M0512) were applied i.p. on days 7–9 and 14–17.
3
Ethanol-induced Colitis Model in NOD-scid IL-2Rγ Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NOD.cg-PrkdcSCID Il2rgtm1Wjl/Szj mice (abbreviated as NOD-scid IL-2Rγnull) were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice were kept under specific pathogen-free conditions in individually ventilated cages. The facility was controlled according to the Federation of Laboratory Animal Science Association (FELASA) guidelines. Following engraftment (day 1), mice were pre-sensitized through rectal application of 150 µl of 10% ethanol on day 8 using a 1-mm cat catheter (Henry Schein, Hamburg, Germany). The catheter was lubricated with Xylocain© Gel 2% (AstraZeneca, Wedel). Rectal application was performed under general anesthesia using 4% isoflurane. Post application, mice were kept at an angle of 30° to avoid ethanol dripping. On days 15 and 18, mice were challenged with rectal application of 50% ethanol following the protocol described for day 8. Mice were killed on day 21. Pitrakinra (10 µg in 0.5% methylcellulose, 0.05% Tween-80) in PBS (Zadeh-Khorasani et al., 2013 (link)) was applied on days 7-9 and 14-21. In these groups, sterile saline (B. Braun Melsungen AG, Germany) served as control. Infliximab [6 mg/kg (Remicade©, Janssen, The Netherlands)] was applied on days 7, 14 and 17. An isotype antibody (human IgG1, kindly provided by, MorphoSys AG) was used as control. All treatments were applied intraperitoneally.
4
Ethanol-Induced Colitis Model in NSG Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NSG mice were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice were kept under specific pathogen–free conditions in individually ventilated cages in a facility controlled according to Federation of Laboratory Animal Science Association (FELASA) guidelines. After engraftment on day 1, mice were presensitized by rectal application of 150 µL of 10% ethanol on day 8 using a 1-mm cat catheter (Henry Schein, Hamburg, Germany). The catheter was lubricated with Xylocain Gel 2% (AstraZeneca, Wedel, Germany). Rectal application was performed under general anesthesia using 4% isofluran. Postapplication, mice were kept at an angle of 30° to avoid ethanol dripping. On day 15, mice were challenged by rectal application of 50% ethanol following the protocol of day 8. On day 18, mice were killed. Adalimumab was provided by Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, Germany) and was applied in PBS (30 mg/kg/d) on days 7 and 14. The control groups were injected with 30 mg/kg of the isotype antibody (Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany) on days 7 and 14.
5
Ethanol-Induced Colitis Model in NOD/scid IL-2Rγ Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NOD/scid IL-2Rγnull mice were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice were kept under specific pathogen-free conditions in individually ventilated cages in a facility controlled according to the Federation of Laboratory Animal Science Association guidelines. Following engraftment (day 1), mice were presensitized by rectal application of 150 µL of 10% ethanol on day 8 using a 1-mm cat catheter (Henry Schein, Hamburg, Germany). The catheter was lubricated with Xylocain Gel 2% (AstraZeneca, Wedel). Rectal application was performed under general anaesthesia using 4% Isofluran. Postapplication, mice were kept at an angle of 30° to avoid ethanol dripping. On days 15 and 18, mice were challenged by rectal application of 50% ethanol following the protocol of day 8. Mice were killed on day 21.
Mice were treated by intraperitoneal application of 30 µg of anti-CD1a antibody (Clone OKT6, BioXcell, West Lebanon, USA) or 30 µg of isotype control (Biolegend, San Diego, CA, USA) on days 7, 14, and 17.
Mice were treated by intraperitoneal application of 30 µg of anti-CD1a antibody (Clone OKT6, BioXcell, West Lebanon, USA) or 30 µg of isotype control (Biolegend, San Diego, CA, USA) on days 7, 14, and 17.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!